Franck Lemiale, PhD, Senior Director of Vaccines and Immunology for VIRxSYS just returned from Los Cabos, Mexico where he presented at HIV DART 2010: Frontiers in Drug Development for Antiretroviral Therapies. The presentation covered all the proprietary lentiviral vector technology utilized in the VRX1273 HIV Vaccine and summarized the preclinical vaccine work performed in non-human primate (NHP) studies. Although we have presented VRX1273 to world class scientific audiences several times before, this was the first time we have been invited to present to such a premier audience of HIV/AIDS clinicians. The presentation was very well received and the follow up panel discussion provoked positive interest. Several experts approached us with proposals to collaborate on such clinical eradication trials. The enthusiasm for our role as an important and unique approach to an HIV cure is very encouraging as we move forward with the development of VRX1273.